Insmed (INSM) Earnings Analysis
Insmed (INSM) next reports earnings on 2026-08-06, consensus EPS -0.7 USD. Last quarter (2026-05-07) it beat with EPS -0.76 USD vs -0.96338 USD est (+21.1%). It has beaten estimates in 1/7 recent quarters (14%). Trailing P/E -18.55.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does INSM next report earnings?
| Next earnings date | 2026-08-06 |
|---|---|
| Consensus EPS estimate | -0.7 USD |
| Revenue estimate | 0.39B |
INSM earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-05-07 | -0.76 USD | -0.96338 USD | +21.1% | Beat |
| 2026-02-19 | -1.54 USD | -1.07 USD | -43.9% | Miss |
| 2025-10-30 | -1.75 USD | -1.33 USD | -31.6% | Miss |
| 2025-05-08 | -1.42 USD | -1.34 USD | -6% | Miss |
| 2025-02-20 | -1.32 USD | -1.17 USD | -12.8% | Miss |
| 2024-10-31 | -1.27 USD | -1.2 USD | -5.8% | Miss |
| 2024-08-08 | -1.94 USD | -1.24 USD | -56.5% | Miss |
Beat rate: 1/7 (14%) over reported quarters with consensus data.
INSM valuation and analyst view
| Trailing P/E | -18.55 |
|---|---|
| Trailing EPS | -5.49388 USD |
| Price / book | 32.60 |
| Dividend yield | 0.00% |
| Market cap | 23.01B |
| Analyst consensus | Buy (33 buy / 1 hold / 1 sell) |
| Avg price target | 190.86 USD |
Related research pages
Frequently asked questions
When is Insmed (INSM)'s next earnings date?
Insmed is next scheduled to report on 2026-08-06, with a consensus EPS estimate of -0.7 USD and revenue estimate of 0.39B.
Did INSM beat earnings last quarter?
In its 2026-05-07 report, INSM posted EPS of -0.76 USD versus a -0.96338 USD estimate — a beat of 21.1%.
What is INSM's earnings track record?
Over the last 7 reported quarters with consensus data, INSM beat estimates 1 times (14%).
What is INSM's current P/E ratio and EPS?
INSM trades at a trailing P/E of -18.55 on trailing EPS of -5.493878441346279 USD.
What do analysts rate INSM?
Analyst consensus is "Buy" across 35 ratings (0 strong buy, 33 buy, 1 hold, 1 sell, 0 strong sell). Average 12-month price target: 190.86 USD.